Acute Ischemic Stroke Pipeline Assessment 2024 | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

DelveInsight's "Acute Ischemic Stroke Pipeline Insight, 2024," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Acute Ischemic Stroke pipeline products in this space.
"Acute Ischemic Stroke Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acute Ischemic Stroke Market.

The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Acute Ischemic Stroke Overview

Acute ischemic stroke (AIS) is a critical medical emergency resulting from a reduction in blood flow to the brain, leading to damage and death of brain cells. It is a major cause of death and disability in the U.S., impacting approximately 700,000 individuals annually. AIS occurs when blood vessels supplying the brain become blocked by a clot or narrowed, obstructing blood flow. This interruption prevents oxygen and nutrients from reaching brain tissue, causing cell death within minutes to hours. The severity of an ischemic stroke and its symptoms depend on the brain region affected and the extent of tissue damage.

Common signs and symptoms of AIS include sudden numbness or weakness in an arm or leg, facial droop, difficulty speaking or understanding speech, confusion, balance or coordination problems, and vision loss. Symptoms can vary, but they typically involve sudden weakness or numbness, especially on one side of the body, confusion, difficulty with speech, visual disturbances, and severe headaches with no obvious cause. Recognizing these symptoms can help healthcare providers identify the affected brain area. Given that stroke symptoms represent a medical emergency, immediate treatment is crucial to minimize brain damage and complications. Sometimes, an acute ischemic stroke is preceded by a transient ischemic attack (TIA), a brief episode of reduced blood flow to the brain.

High blood pressure is the primary risk factor for AIS, with additional risks including previous TIAs, smoking, high cholesterol, diabetes, obesity, end-stage kidney disease, and atrial fibrillation, a heart rhythm disorder.

Diagnosing an acute ischemic stroke involves a detailed medical history, physical examination, and diagnostic imaging. CT scans and MRIs are essential for identifying the type of stroke and assessing the affected brain areas. Treatment aims to restore blood flow to the brain as quickly as possible. This may involve thrombolytics (clot-busting drugs), mechanical clot removal in some cases, and medications to prevent further clots. Rehabilitation, including physical, occupational, and speech therapy, is often necessary to help patients regain strength, mobility, and communication abilities. The goal of treatment is to preserve brain tissue in areas with reduced blood flow but not yet infarcted, by restoring blood flow and enhancing collateral circulation. Effective recanalization strategies, such as recombinant tissue-type plasminogen activator, can reduce ischemic damage if administered promptly. Timely intervention is critical for improving recovery outcomes, highlighting the importance of seeking immediate medical attention for stroke symptoms.

Acute Ischemic Stroke Pipeline Analysis [https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

The report provides insights into:

*
The report provides detailed insights into the emerging therapies for the treatment of Acute Ischemic Stroke and the aggregate therapies developed by major pharma companies.

*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acute Ischemic Stroke market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Acute Ischemic Stroke Products have been categorized under various ROAs such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Molecule Type

Acute Ischemic Stroke Products have been categorized under various Molecule types such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Acute Ischemic Stroke Therapeutic Segment @ https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight [https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Acute Ischemic Stroke Emerging Drugs [https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

*
Nelonemdaz: GNT Pharma

*
Glenzocimab : Acticor Biotech

*
NoNO-42: NoNO Inc.

There are approx. 30+ key Acute Ischemic Stroke companies which are developing the Acute Ischemic Stroke therapies. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, GNT Pharma.

Leading Players in the Acute Ischemic Stroke Therapeutics Market are AbbVie, Acticor Biotech, Angde Biotech Pharmaceutical, aptaTargets, Athersys|Healios K.K., Bayer, Biogen, Biogen Inc., Bristol-Myers Squibb, Clinuvel Pharmaceuticals, DiaMedica Therapeutics, Genentech, Inc., GNT Pharma, Healios, Janssen Pharmaceutical, JCR Pharmaceuticals, Lumosa Therapeutics, NC Medical Research, NoNO Inc., NuvOx Pharma, Pharmazz, Pharming Group, PT. Prodia Stem Cell Indonesia, Revalesio Corporation, Roche, Shin Poong Pharmaceutical, Shionogi & Co., Ltd., Silver Creek Pharmaceuticals, Supergene, Tasly Pharmaceutical, TrueBinding, Inc, ZZ Biotech, and others.

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight [https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Acute Ischemic Stroke Current Treatment Patterns

4. Acute Ischemic Stroke - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Acute Ischemic Stroke Late Stage Products (Phase-III)

7. Acute Ischemic Stroke Mid-Stage Products (Phase-II)

8. Acute Ischemic Stroke Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acute Ischemic Stroke Discontinued Products

13. Acute Ischemic Stroke Product Profiles

14. Key Companies in the Acute Ischemic Stroke Market

15. Key Products in the Acute Ischemic Stroke Therapeutics Segment

16. Dormant and Discontinued Products

17. Acute Ischemic Stroke Unmet Needs

18. Acute Ischemic Stroke Future Perspectives

19. Acute Ischemic Stroke Analyst Review

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-ischemic-stroke-pipeline-assessment-2024-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-ema-and-pmda-approvals-competitive-landscape-key-companies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.